<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00748020</url>
  </required_header>
  <id_info>
    <org_study_id>UVB-MKL</org_study_id>
    <nct_id>NCT00748020</nct_id>
  </id_info>
  <brief_title>Narrow-Band UVB-Therapy in Psoriasis</brief_title>
  <official_title>Narrow-Band UVB-Therapy in Psoriasis: Randomised Double-Blind Comparison of Erythematogenic and Suberythematogenic Irradiation Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study on two different irradiation schemes in UVB phototherapy for psoriasis. Previous
      studies demonstrated a similar clinical effect in erythematogenic and suberythematogenic
      irradiation, with less complications in suberythematogenic irradiation. Most of these studies
      used both irradiation schemes within the same patient. UVB has a systemic effect on the body.
      Our hypothesis is that previous conclusions are incorrect and that the erythematogenic scheme
      will result in earlier clearance of the psoriasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      109 psoriasis patients, referred for UVB phototherapy, participated in our study after given
      their written informed consent. After determining the minimal erythema dose (MED) patients
      were randomised in either group 1, erythematogenic scheme, or group 2, suberythematogenic
      scheme. Group 1 started with 70% of MED and every following irradiation with an increase of
      40%. Group 2 started with 30% of MED and every next visit an increase of 20%. The study
      protocol was adjusted in case of erythema (sunburn) according to a standard
      erythema-phototherapy protocol, varying from skip one irradiation to lowering the percentage
      of increase. In case of clearance the study stopped. Clearance was defined as less than 10%
      of baseline body area of psoriasis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clearance is defined as less than 10% affected body area with psoriasis compared with baseline</measure>
    <time_frame>every 4 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">109</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Erythematogenic irradiation scheme</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Suberythematogenic irradiation scheme</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>UVB phototherapy</intervention_name>
    <description>Group 1: every irradiation an increase of 40%, starting with 70% of the minimal erythema dose</description>
    <arm_group_label>group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>UVB phototherapy</intervention_name>
    <description>Group 2: every irradiation an increase of 20%, starting with 30% of the minimal erythema dose</description>
    <arm_group_label>group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible for UVB phototherapy

          -  Older than 18 years

        Exclusion Criteria:

          -  No topical medication for 2 weeks

          -  No systemic medication for 4 weeks

          -  No medication (betablocker, lithium) interfering with psoriasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rianne Gerritsen, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University Nijmegen Medical Centre, Department of Dermatology</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2008</study_first_submitted>
  <study_first_submitted_qc>September 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2008</study_first_posted>
  <last_update_submitted>September 5, 2008</last_update_submitted>
  <last_update_submitted_qc>September 5, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2008</last_update_posted>
  <responsible_party>
    <name_title>M.J.P. Gerritsen, MD, PhD</name_title>
    <organization>Radboud University Nijmegen Medical Centre</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

